1213329-40-8 Usage
General Description
The chemical (1R)-1-(4-Fluorophenyl)-2-methylpropylamine-HCl, also known as fluoxetine hydrochloride, is a selective serotonin reuptake inhibitor (SSRI) used to treat major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder. It works by increasing the levels of serotonin in the brain, which helps to improve mood, appetite, and energy levels. It is typically prescribed in capsule form to be taken orally, and the dosage is determined by the individual's medical condition and response to treatment. Possible side effects include dizziness, drowsiness, nausea, and sexual dysfunction. It is important to follow the prescribed dosage and to avoid suddenly stopping the medication, as this may lead to withdrawal symptoms. Additionally, it should not be taken with certain other medications and medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1213329-40-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,3,3,2 and 9 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1213329-40:
(9*1)+(8*2)+(7*1)+(6*3)+(5*3)+(4*2)+(3*9)+(2*4)+(1*0)=108
108 % 10 = 8
So 1213329-40-8 is a valid CAS Registry Number.
1213329-40-8Relevant articles and documents
Synthesis and pharmacological evaluation of 1-Alkyl-N-[(1R)-1-(4- fluorophenyl)-2-methylpropyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents
Watanuki, Susumu,Matsuura, Keisuke,Tomura, Yuichi,Okada, Minoru,Okazaki, Toshio,Ohta, Mitsuaki,Tsukamoto, Shin-Ichi
, p. 1376 - 1385 (2012/01/05)
We synthesized and evaluated inhibitory activity against T-type Ca 2+ channels for a series of 1-alkyl-N- [(1R)-1-(4-fluorophenyl)-2- methylpropyl]piperidine-4-carboxamide derivatives. Structure-activity relationship studies have revealed that the isopropyl substituent at the benzylic position plays an important role in exerting potent inhibitory activity, and the absolute configuration of the benzylic position was found to be opposite that of mibefradil, which was first launched as a new class of T-type Ca2+ channel blocker. Oral administration of N- [(1R)-1-(4-fluorophenyl)-2-methylpropyl]-1-[2-(3-methoxyphenyl)ethyl] piperidine-4-carboxamide (17f) lowered blood pressure in spontaneously hypertensive rats without inducing reflex tachycardia, an adverse effect often caused by traditional L-type Ca2+ channel blockers.
